← Adverse-Event Coding & Causality
Clinical / Pharmacovigilance · Drug-safety physician (PV)

Adverse-Event Coding & Causality — agent trajectory for expert review

claude-opus-4-8 · 2026-06-06T09:14:36.690997+00:00 · 10 tool calls · 31.6s · 11657 tokens
run id: ae_causality_20260606_021404_01_code-the-adverse-events-to-meddra-pt-soc-and-ass

Query

Code the adverse events to MedDRA PT/SOC and assess seriousness and drug causality for case ICSR-001 (a patient on a DLL3 T-cell engager). Justify each causality category.

Trajectory

Agent · turn 1

I'll start by pulling the case and the drug label in parallel, then code the events.

⚙ calls get_case(case_id=ICSR-001)
⚙ calls get_drug_label(drug_class=DLL3 T-cell engager (BiTE))
↳ get_case result
show data
{
  "case_id": "ICSR-001",
  "study_drug": "Tarlatamab",
  "drug_class": "DLL3 T-cell engager (BiTE)",
  "patient": {
    "age": 64,
    "sex": "M",
    "comorbidities": [
      "ES-SCLC, 2nd line",
      "former smoker"
    ],
    "concomitant_meds": [
      "dexamethasone premedication",
      "ondansetron"
    ]
  },
  "narrative": "64-year-old man with extensive-stage small cell lung cancer received his first step-up dose of the DLL3 T-cell engager. Approximately 8 hours after dosing he developed fever to 39.2C with rigors and low blood pressure (88/54) requiring IV fluids; this was graded as cytokine release syndrome. On day 2 nursing noted he was confused with a coarse tremor and a drop in his ICE score (neurotoxicity). He was admitted to hospital and treated with tocilizumab and steroids; symptoms resolved over 48 hours. He was re-dosed at the next cycle with premedication and had only mild recurrence. No infection was identified on workup.",
  "events": [
    "fever with low blood pressure (CRS)",
    "confusion with tremor (neurotoxicity)"
  ]
}
↳ get_drug_label result
show data
{
  "drug_class": "DLL3 T-cell engager (BiTE)",
  "examples": [
    "Tarlatamab"
  ],
  "labeled": [
    "Cytokine release syndrome",
    "Immune effector cell-associated neurotoxicity syndrome",
    "Pyrexia",
    "Neutropenia",
    "Anaemia",
    "Fatigue",
    "Hypotension"
  ],
  "boxed_warning": "Cytokine release syndrome and neurologic toxicity including ICANS.",
  "note": "CRS and ICANS are expected, very common, on-target effects of T-cell engagers; typically occur within days of the first/step-up doses."
}
Agent · turn 2

Now let me code the individual clinical events to MedDRA PTs.

⚙ calls meddra_lookup(term=cytokine release syndrome)
⚙ calls meddra_lookup(term=fever)
⚙ calls meddra_lookup(term=low blood pressure)
⚙ calls meddra_lookup(term=rigors)
⚙ calls meddra_lookup(term=confusion)
⚙ calls meddra_lookup(term=tremor)
⚙ calls meddra_lookup(term=neurotoxicity)
↳ meddra_lookup result
show data
{
  "query": "cytokine release syndrome",
  "count": 1,
  "matches": [
    {
      "pt": "Cytokine release syndrome",
      "soc": "Immune system disorders",
      "synonyms": [
        "crs",
        "cytokine storm",
        "infusion cytokine reaction"
      ]
    }
  ]
}
↳ meddra_lookup result
show data
{
  "query": "fever",
  "count": 2,
  "matches": [
    {
      "pt": "Febrile neutropenia",
      "soc": "Blood and lymphatic system disorders",
      "synonyms": [
        "fever with low white count",
        "neutropenic fever"
      ]
    },
    {
      "pt": "Pyrexia",
      "soc": "General disorders and administration site conditions",
      "synonyms": [
        "fever",
        "high temperature",
        "febrile",
        "raised temperature"
      ]
    }
  ]
}
↳ meddra_lookup result
show data
{
  "query": "low blood pressure",
  "count": 1,
  "matches": [
    {
      "pt": "Hypotension",
      "soc": "Vascular disorders",
      "synonyms": [
        "low blood pressure",
        "low bp"
      ]
    }
  ]
}
↳ meddra_lookup result
show data
{
  "query": "rigors",
  "count": 0,
  "matches": []
}
↳ meddra_lookup result
show data
{
  "query": "confusion",
  "count": 1,
  "matches": [
    {
      "pt": "Immune effector cell-associated neurotoxicity syndrome",
      "soc": "Nervous system disorders",
      "synonyms": [
        "icans",
        "neurotoxicity",
        "neurologic toxicity",
        "confusion with tremor",
        "encephalopathy",
        "ice score drop"
      ]
    }
  ]
}
↳ meddra_lookup result
show data
{
  "query": "tremor",
  "count": 1,
  "matches": [
    {
      "pt": "Immune effector cell-associated neurotoxicity syndrome",
      "soc": "Nervous system disorders",
      "synonyms": [
        "icans",
        "neurotoxicity",
        "neurologic toxicity",
        "confusion with tremor",
        "encephalopathy",
        "ice score drop"
      ]
    }
  ]
}
↳ meddra_lookup result
show data
{
  "query": "neurotoxicity",
  "count": 1,
  "matches": [
    {
      "pt": "Immune effector cell-associated neurotoxicity syndrome",
      "soc": "Nervous system disorders",
      "synonyms": [
        "icans",
        "neurotoxicity",
        "neurologic toxicity",
        "confusion with tremor",
        "encephalopathy",
        "ice score drop"
      ]
    }
  ]
}
Agent · turn 3

Let me check one more term for completeness.

⚙ calls meddra_lookup(term=chills)
↳ meddra_lookup result
show data
{
  "query": "chills",
  "count": 0,
  "matches": []
}
Agent · turn 4

ICSR-001 — Adverse Event Coding, Seriousness & Causality Assessment

Patient: 64 y/o male, ES-SCLC (2nd line), former smoker
Study drug: Tarlatamab (DLL3 T-cell engager / BiTE)
Concomitant: dexamethasone premed, ondansetron

Event Coding & Clinical Construct

The narrative describes two clinical syndromes, each with a defining MedDRA PT plus component-symptom PTs. Best practice is to code the diagnostic umbrella term when a syndrome is explicitly diagnosed, and capture the component signs as separate PTs where informative.

Event 1 — "Fever to 39.2 °C with rigors and hypotension, graded as CRS"

Sign / diagnosis MedDRA PT SOC Role
CRS (diagnosis) Cytokine release syndrome Immune system disorders Primary umbrella PT
Fever 39.2 °C Pyrexia General disorders & admin site conditions Component sign
Hypotension 88/54 Hypotension Vascular disorders Component sign
Rigors (no exact PT returned; would map to Chills / Pyrexia — flag for dictionary verification) General disorders Component sign

Note: I avoided coding the fever as Febrile neutropenia — there is no neutrophil count in the narrative and "no infection was identified," so that PT is not supported by source data.

Event 2 — "Day-2 confusion with coarse tremor and ICE-score drop (neurotoxicity)"

Sign / diagnosis MedDRA PT SOC Role
Neurotoxicity / ICE drop Immune effector cell-associated neurotoxicity syndrome (ICANS) Nervous system disorders Primary umbrella PT

Confusion, tremor and the ICE-score drop all map (per the teaching dictionary synonyms) to the ICANS PT, so they are captured under the single syndrome term rather than splitting.

Seriousness Assessment (ICH E2A criteria)

Event (PT) Serious? Seriousness criterion met
Cytokine release syndrome YES Hospitalization (admitted); also life-threatening physiology (hypotension/rigors requiring IV fluids + tocilizumab)
ICANS YES Hospitalization; medically important neurologic event requiring intervention
Pyrexia / Hypotension (components) Serious as part of the serious CRS event Captured under the CRS hospitalization

Case is SERIOUS — driven by inpatient hospitalization (an E2A seriousness criterion) and the medically-important, intervention-requiring nature of both syndromes.

Causality Assessment (per event)

Drug-class label confirms: CRS and ICANS are labeled, very common, on-target, boxed-warning effects of DLL3 T-cell engagers, typically within days of the first/step-up dose.

CRS → Related / Probable

Justification:
- Temporal plausibility: onset ~8 h after the first step-up dose — classic window for BiTE-induced CRS.
- Biological mechanism: CRS is an on-target, expected pharmacologic consequence of T-cell engagement (boxed warning).
- Dechallenge: resolved within 48 h with tocilizumab + steroids (a CRS-directed therapy), supporting drug attribution.
- Positive rechallenge: re-dosed next cycle with only mild recurrence — rechallenge reproduced the reaction (with premedication mitigation), a strong causality signal.
- Alternative cause excluded: "no infection identified on workup," reducing sepsis as a confounder.

ICANS → Related / Probable

Justification:
- Temporal plausibility: day-2 onset, immediately following CRS — the canonical CRS→ICANS sequence for T-cell engagers.
- Mechanism: neurologic toxicity/ICANS is a labeled, boxed-warning effect of the class.
- Dechallenge: resolved over 48 h with steroids.
- Alternative causes: no CNS infection/metabolic cause identified; concomitant meds (dexamethasone, ondansetron) are not plausible causes of an ICANS-type encephalopathy.

Confounder / Concomitant-Drug Note

Summary Line for the ICSR

Serious case (hospitalization). Two events coded: Cytokine release syndrome (Immune system disorders) and Immune effector cell-associated neurotoxicity syndrome (Nervous system disorders), with component PTs Pyrexia and Hypotension. Both events assessed Related (probable) to tarlatamab — labeled boxed-warning on-target reactions, plausible temporality to the step-up dose, positive dechallenge, positive rechallenge for CRS, and exclusion of infection.


Caveats: "Rigors" did not return an exact PT in the teaching dictionary — verify mapping (likely Chills) in the production MedDRA browser. CRS and ICANS should also be grade-staged (ASTCT) at the company level if grading fields are required.

Final output

ICSR-001 — Adverse Event Coding, Seriousness & Causality Assessment

Patient: 64 y/o male, ES-SCLC (2nd line), former smoker
Study drug: Tarlatamab (DLL3 T-cell engager / BiTE)
Concomitant: dexamethasone premed, ondansetron

Event Coding & Clinical Construct

The narrative describes two clinical syndromes, each with a defining MedDRA PT plus component-symptom PTs. Best practice is to code the diagnostic umbrella term when a syndrome is explicitly diagnosed, and capture the component signs as separate PTs where informative.

Event 1 — "Fever to 39.2 °C with rigors and hypotension, graded as CRS"

Sign / diagnosis MedDRA PT SOC Role
CRS (diagnosis) Cytokine release syndrome Immune system disorders Primary umbrella PT
Fever 39.2 °C Pyrexia General disorders & admin site conditions Component sign
Hypotension 88/54 Hypotension Vascular disorders Component sign
Rigors (no exact PT returned; would map to Chills / Pyrexia — flag for dictionary verification) General disorders Component sign

Note: I avoided coding the fever as Febrile neutropenia — there is no neutrophil count in the narrative and "no infection was identified," so that PT is not supported by source data.

Event 2 — "Day-2 confusion with coarse tremor and ICE-score drop (neurotoxicity)"

Sign / diagnosis MedDRA PT SOC Role
Neurotoxicity / ICE drop Immune effector cell-associated neurotoxicity syndrome (ICANS) Nervous system disorders Primary umbrella PT

Confusion, tremor and the ICE-score drop all map (per the teaching dictionary synonyms) to the ICANS PT, so they are captured under the single syndrome term rather than splitting.

Seriousness Assessment (ICH E2A criteria)

Event (PT) Serious? Seriousness criterion met
Cytokine release syndrome YES Hospitalization (admitted); also life-threatening physiology (hypotension/rigors requiring IV fluids + tocilizumab)
ICANS YES Hospitalization; medically important neurologic event requiring intervention
Pyrexia / Hypotension (components) Serious as part of the serious CRS event Captured under the CRS hospitalization

Case is SERIOUS — driven by inpatient hospitalization (an E2A seriousness criterion) and the medically-important, intervention-requiring nature of both syndromes.

Causality Assessment (per event)

Drug-class label confirms: CRS and ICANS are labeled, very common, on-target, boxed-warning effects of DLL3 T-cell engagers, typically within days of the first/step-up dose.

CRS → Related / Probable

Justification:
- Temporal plausibility: onset ~8 h after the first step-up dose — classic window for BiTE-induced CRS.
- Biological mechanism: CRS is an on-target, expected pharmacologic consequence of T-cell engagement (boxed warning).
- Dechallenge: resolved within 48 h with tocilizumab + steroids (a CRS-directed therapy), supporting drug attribution.
- Positive rechallenge: re-dosed next cycle with only mild recurrence — rechallenge reproduced the reaction (with premedication mitigation), a strong causality signal.
- Alternative cause excluded: "no infection identified on workup," reducing sepsis as a confounder.

ICANS → Related / Probable

Justification:
- Temporal plausibility: day-2 onset, immediately following CRS — the canonical CRS→ICANS sequence for T-cell engagers.
- Mechanism: neurologic toxicity/ICANS is a labeled, boxed-warning effect of the class.
- Dechallenge: resolved over 48 h with steroids.
- Alternative causes: no CNS infection/metabolic cause identified; concomitant meds (dexamethasone, ondansetron) are not plausible causes of an ICANS-type encephalopathy.

Confounder / Concomitant-Drug Note

Summary Line for the ICSR

Serious case (hospitalization). Two events coded: Cytokine release syndrome (Immune system disorders) and Immune effector cell-associated neurotoxicity syndrome (Nervous system disorders), with component PTs Pyrexia and Hypotension. Both events assessed Related (probable) to tarlatamab — labeled boxed-warning on-target reactions, plausible temporality to the step-up dose, positive dechallenge, positive rechallenge for CRS, and exclusion of infection.


Caveats: "Rigors" did not return an exact PT in the teaching dictionary — verify mapping (likely Chills) in the production MedDRA browser. CRS and ICANS should also be grade-staged (ASTCT) at the company level if grading fields are required.

Reference answer key (deterministic) — open after grading

Deterministic reference key for ICSR-001 (Tarlatamab). Causality categories follow WHO-UMC; where the narrative supports more than one defensible category the rationale says so. A strong analyst recovers all events, the correct PT/SOC from the dictionary, the right seriousness criterion, and well-reasoned causality grounded in temporality, dechallenge/rechallenge, alternative etiology, and the drug label.

Event (as narrated)Expected PTExpected SOCSeriousness (ICH E2A)Causality (WHO-UMC) + rationale
fever with low blood pressure (CRS)Cytokine release syndromeImmune system disordersSerious — Hospitalization (and medically important)Probable — Onset hours after the first step-up dose (tight temporal link), CRS is a labeled/boxed on-target effect of T-cell engagers, no infection found (no alternative cause), positive dechallenge with tocilizumab/steroids and only mild recurrence on rechallenge with premedication. Strong case; 'Certain' is defensible if rechallenge is weighted heavily.
confusion with tremor (neurotoxicity)Immune effector cell-associated neurotoxicity syndromeNervous system disordersSerious — Hospitalization (and medically important)Probable — Onset day 2 after dosing, ICANS-type neurotoxicity is a labeled/boxed class effect, resolved with steroids (positive dechallenge), no metabolic or structural alternative identified.
OVERALL CASESerious — Hospitalization / initially life-threatening (CRS with hypotension)Case-level ICH-E2A determination

Expert grading

Event extraction completeness 1 (poor) 5 (excellent)
5: Identifies every reportable adverse event in the narrative — including a serious event that is unrelated to the drug and secondary/lab events — without lumping distinct events or inventing ones.
1: Misses reportable events (e.g. overlooks the neutropenia behind a febrile-neutropenia admission, or drops the unrelated fracture), or merges separate events into one.
MedDRA coding accuracy 1 (poor) 5 (excellent)
5: Maps each lay event to the correct Preferred Term and its System Organ Class using the dictionary lookup (e.g. 'low white count' -> Neutropenia / Blood and lymphatic system disorders; 'shortness of breath with infiltrates' -> Pneumonitis / Respiratory). PT and SOC are consistent with the dictionary, not guessed from memory.
1: Wrong PT or mismatched SOC, codes to a symptom when a diagnosis PT exists (or vice versa), or fabricates a code never returned by meddra_lookup.
Seriousness determination (ICH E2A) 1 (poor) 5 (excellent)
5: Correctly classifies each event as serious/non-serious and names the right ICH E2A criterion (death, life-threatening, hospitalization, disability, congenital anomaly, medically important) — e.g. flags the hospitalized CRS/pneumonitis/febrile-neutropenia events as serious and the asymptomatic resolved lab abnormality as non-serious.
1: Calls a clearly serious (hospitalized/life-threatening) event non-serious or vice versa, or cites the wrong/no criterion, or conflates severity grade with seriousness.
Causality assessment quality (WHO-UMC) 1 (poor) 5 (excellent)
5: Assigns a defensible WHO-UMC category with sound reasoning: weighs temporality (onset vs dosing), dechallenge/rechallenge, alternative etiologies (confounding meds, comorbidity, trauma), and whether the event is labeled — e.g. probable/certain for step-up-dose CRS, unlikely for the antibiotic-confounded transaminitis, unrelated for the traumatic fracture.
1: Reflexively blames or exonerates the drug, ignores a strong alternative etiology or the temporal mismatch, conflates seriousness with causality, or misuses the WHO-UMC categories.
Evidence faithfulness 1 (poor) 5 (excellent)
5: Grounds every PT/SOC in an actual meddra_lookup result and every causality factor in the narrative or the drug label; no invented events, codes, lab values, or label claims; states uncertainty where the narrative is genuinely ambiguous.
1: Invents events or MedDRA codes, asserts label content not returned by get_drug_label, or contradicts the narrative (wrong timing, fabricated dechallenge).
Overall verdict
Your name / ID